证券代码：300583 证券简称：赛托生物 公告编号：2024-031 山东赛托生物科技股份有限公司 关于股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、股票交易异常波动的具体情况 山东赛托生物科技股份有限公司（以下简称"公司"）股票交易价格于 2024 年 7 月 29 日、7 月 30 日连续两个交易日收盘价格涨幅偏离值累计超过 30%，根据 《深圳证券交易所交易规则》等相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票交易异常波动情况，公司董事会对相关事项进行了核实，现说明 如下： 三、是否存在应披露而未披露信息的说明 公司董事会确认，截至本公告日，本公司目前没有根据《深圳证券交易所创业 板股票上市规则（2024 年修订）》（以下简称"上市规则"）等有关规定应予以披露 而未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董事会也未获悉本 公司有根据《上市规则》等有关规定应予以披露而未披露的、对本公司股票及其衍 生品种交易价格产生较大影响的信息；公司前期披露的信息不存在需要更正、补充 之处。 四 ...

证券代码：300583 证券简称：赛托生物 公告编号：2024-030 山东赛托生物科技股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）2023 年年度权益分派 方案已获 2024 年 6 月 21 日召开的 2023 年年度股东大会审议通过，现将权益分派 事宜公告如下： 个月（含 1 个月）以内，每 10 股补缴税款 0.900000 元；持股 1 个月以上至 1 年（含 1 年）的，每 10 股补缴税款 0.450000 元；持股超过 1 年的，不需补缴税款。】 三、股权登记日与除权除息日 本次权益分派股权登记日为：2024 年 7 月 29 日，除权除息日为：2024 年 7 月 30 日。 一、股东大会审议通过利润分配方案情况 1、公司 2023 年年度股东大会审议通过 2023 年年度利润分配方案：公司以 189,702,126股为基数，向全体股东每10股派发现金股利人民币4.50元（含税）， 共计派发现金红利 85,365,956.70 元（含税），本次 ...

证券代码：300583 证券简称：赛托生物 编号：2024-023 山东赛托生物科技股份有限公司 关于子公司收到化学原料药上市申请批准通知书的公告 申请事项：境内生产化学原料药上市申请 生产企业：山东斯瑞药业有限公司 生产地址：山东省菏泽市定陶区东外环路南段 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准生产本品。质量标准、标签及生产工艺照所附执 行。 与制剂关联审评审批结果：A 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司近日收到国家药品监督管理局签发的丙酸氟替卡松《化学原料药上 市申请批准通知书》，现将相关情况公告如下： 一、原料药登记信息 化学原料药名称：丙酸氟替卡松/Fluticasone Propionate 登记号：Y20200000871 包装规格：0.5kg/桶，1.0kg/桶，2.0kg/桶 四、报备文件 《化学原料药上市申请批准通知书》 特此公告。 二、原料药的相关情况 丙酸氟替卡松原料药可以用于生产丙酸氟替 ...

证券代码：300583 证券简称：赛托生物 编号：2024-022 山东赛托生物科技股份有限公司 关于子公司收到化学原料药欧洲CEP证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司（以下简称"斯瑞药业"）近日收到欧洲药品质量管理局（以下简 称"EDQM"）签发的原料药欧洲药典适用性证书（以下简称"CEP 证书"），现将 相关情况公告如下： 一、原料药注册批件信息 化学原料药名称：FLUTICASONE PROPIONATE 丙酸氟替卡松 生产地址：山东省菏泽市定陶区东外环路南段 证书编号：CEP2022-282-Rev00 发证机关：欧洲药品质量管理局（EDQM） 有效期：自 2024 年 5 月 3 日起五年内有效 二、原料药的相关情况 丙酸氟替卡松原料药可以用于生产丙酸氟替卡松相关剂型药品，丙酸氟替卡 松乳膏剂可用于缓解用于缓解对糖皮质激素有应答的皮肤病的炎症和瘙痒症状， 吸入剂可用于缓解哮喘相关症状，鼻喷剂可用于预防和治疗季节性过敏性鼻炎和 常年性过敏性鼻炎。 公 ...

Investment Rating - The report maintains a "Buy" rating for the company, with an expected relative outperformance of over 20% compared to the benchmark index within the next 6 months [16][22] Core Views - The company's intermediate product prices are stabilizing and recovering, and the API (active pharmaceutical ingredient) sector is entering a harvest period, contributing to revenue and profit growth [4][19] - The construction of the formulation plant is progressing steadily, and the acquisition of Yingu Pharmaceutical is on track, which will help the company expand into the formulation sector and achieve synergies with existing businesses [5][26] - The company's high-margin, high-value-added intermediate products are expected to strengthen its leading position in the steroid intermediate segment [19] - The company's API business is gaining momentum, with several products already approved or under review, including Fluticasone Propionate and Budesonide [19] Financial Performance and Projections - In 2023, the company reported revenue of RMB 1.28 billion (-2.46% YoY) and net profit attributable to the parent company of RMB 45.6 million (+8.67% YoY) [18] - For 2024-2026, the company is projected to achieve revenue of RMB 1.38 billion, RMB 1.51 billion, and RMB 1.67 billion, with YoY growth rates of 7.83%, 9.53%, and 10.72%, respectively [6] - Net profit attributable to the parent company is expected to grow to RMB 59.13 million, RMB 76.35 million, and RMB 89.84 million in 2024-2026, with growth rates of 29.65%, 29.13%, and 17.67%, respectively [6] - EPS is projected to increase from RMB 0.24 in 2023 to RMB 0.31, RMB 0.40, and RMB 0.47 in 2024-2026 [6] - The company's P/E ratio is expected to decline from 61.19 in 2023 to 47.20, 36.55, and 31.06 in 2024-2026, reflecting improved valuation metrics [6] Business Highlights - The company's steroid intermediate business generated revenue of RMB 1.125 billion in 2023, with a gross margin of 23.98%, up 0.49 percentage points YoY [19] - The company has a diversified product portfolio in the intermediate sector, including five core mother nuclei series and over ten high-end intermediates [19] - In the API sector, the company has obtained production licenses for nine products, including Fluticasone Propionate and Budesonide, with several under review [19] - The company's finished drug business achieved revenue of RMB 100 million in 2023, up 27.16% YoY, with two imported drugs, Triamcinolone Acetonide and Calcitonin Salmon, already on the market [26] - The acquisition of Yingu Pharmaceutical, which has three formulation products including a Class 1.1 innovative drug, is expected to enhance the company's formulation capabilities and extend its industrial chain [26] Valuation and Recommendations - The report recommends a "Buy" rating, with a target PE of 47.20x, 36.55x, and 31.06x for 2024-2026, based on the company's growth prospects and improving financial performance [26]

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Insights - In 2023, the company achieved a revenue of 1.28 billion yuan, a year-on-year decrease of 2.46%, while the net profit attributable to shareholders was 45.6 million yuan, an increase of 8.67% [2]. - For Q1 2024, the company reported a revenue of 244 million yuan, a year-on-year decline of 27.00%, and a net profit of 3.07 million yuan, down 80.00% year-on-year [2]. - The company is a leader in the steroid raw material drug segment and is focused on building a complete industrial chain, covering five major series of steroid raw materials [2]. - The company has obtained production licenses for nine raw materials in the high-end respiratory drug sector and is currently undergoing separate reviews for four additional raw materials [2]. - The company plans to acquire 60% of Yingu Pharmaceutical, which will enhance its clinical development capabilities and production capacity in the respiratory drug sector [2]. - The company forecasts revenues of 1.404 billion, 1.538 billion, and 1.669 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 57 million, 73 million, and 84 million yuan [2][3]. Financial Summary - The company’s revenue is projected to grow at rates of 9.70%, 9.50%, and 8.50% for the years 2024, 2025, and 2026, respectively [3]. - The net profit is expected to grow by 25.59%, 27.70%, and 15.08% for the same years [3]. - The earnings per share (EPS) is forecasted to be 0.30 yuan in 2024, 0.39 yuan in 2025, and 0.44 yuan in 2026 [3]. - The price-to-earnings (PE) ratio is projected to decrease from 57 in 2023 to 31 in 2026 [3].

证券代码：300583 证券简称：赛托生物 编号：2024-017 一、本次关联交易概述 山东赛托生物科技股份有限公司（以下简称"公司"）为满足公司经营和发 展需要，拟向控股股东山东润鑫投资有限公司（以下简称"山东润鑫"）借款不 超过人民币 20,000.00 万元，用于补充流动资金，借款利率为山东润鑫实际融资 利率，且年化利率不超过 5.50%。计息方式按照借款实际使用金额和天数计息， 在股东大会审议通过后的 24 个月内循环滚动使用。 上述事项已经公司于 2024 年 4 月 25 日召开的第四届董事会第三次会议及 第四届监事会第三次会议审议通过，关联董事米奇先生回避表决。该议案已经公 司独立董事专门会议审议通过，保荐机构国金证券股份有限公司对该事项发表了 无异议的核查意见。 本项关联交易尚需提交股东大会审议，关联股东山东润鑫投资有限公司、米 超杰先生、米奇先生、米嘉女士需回避表决。 本次关联交易不构成《上市公司重大资产重组管理办法》规定的重大资产重 组，无需经过有关部门批准。 | 公司名称 | 山东润鑫投资有限公司 | | --- | --- | | 登记机关 | 菏泽市定陶区市场监督管理局 | | 统 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,279,783,092, a decrease of 2.46% compared to CNY 1,312,111,876 in 2022[18]. - The net profit attributable to shareholders for 2023 was CNY 45,603,990, representing an increase of 8.67% from CNY 41,979,286 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 24,529,004, a decrease of 32.70% compared to CNY 36,459,930 in 2022[18]. - The net cash flow from operating activities for 2023 was negative CNY 92,845,544, a decline of 163.88% from positive CNY 145,335,684 in 2022[18]. - Basic earnings per share for 2023 were CNY 0.25, an increase of 4.17% from CNY 0.24 in 2022[18]. - Total assets at the end of 2023 amounted to CNY 3,240,242,403, an increase of 8.16% from CNY 2,995,140,143 at the end of 2022[18]. - The net assets attributable to shareholders at the end of 2023 were CNY 2,012,156,809, reflecting a growth of 16.98% from CNY 1,720,156,000 at the end of 2022[18]. - The company achieved a revenue of CNY 1,279.78 million and a net profit of CNY 45.60 million for the fiscal year 2023[51]. Cash Flow and Investments - The company reported a net cash flow from operating activities of approximately CNY 10.70 million in Q1 2023, but it experienced a significant outflow of approximately CNY 128.07 million in Q2 2023[21]. - The net cash inflow from financing activities increased by 6,509.92% to ¥319,769,380.56, primarily due to the completion of a private placement[75]. - The company has invested over CNY 300 million in R&D since its establishment, resulting in 98 patents, including 28 invention patents[48]. - The total investment amount for the reporting period was ¥98,073,041.06, a decrease of 7.54% compared to ¥106,072,878.58 in the same period last year[85]. - The company has committed to using idle raised funds solely for operations related to its main business[102]. Market and Industry Trends - The pharmaceutical industry is undergoing significant reforms, with over 200 national policies and approximately 1,400 provincial policies impacting procurement and drug pricing[29]. - The pharmaceutical manufacturing segment contributed ¥1.23 billion, accounting for 95.74% of total revenue, with a year-on-year decline of 1.35%[60]. - In 2023, the pharmaceutical industry faced a temporary adjustment, with a significant decline in export delivery value by 16.3% year-on-year, impacting overall revenue and profit trends[31]. - The global steroid drug market reached $147.5 billion in 2021, with a compound annual growth rate of 8.71% over the past decade, indicating strong growth potential in the sector[32]. Product Development and R&D - The company has established a full industrial chain strategy, integrating intermediates, raw materials, and finished formulations, enhancing its competitive edge[43][45]. - The company has completed the registration of 9 raw materials in the domestic market and is in the process of applying for production licenses for several others, including five in the US DMF and two in the EU CEP[52][53]. - The company has developed a comprehensive product line in the intermediate sector, covering five major steroid raw material series, establishing a strong market presence[36]. - The company has made significant advancements in its production processes, adopting international GMP standards to ensure product quality[47]. Risk Management and Compliance - The company has outlined potential risk factors and corresponding countermeasures in its future development outlook[6]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the last three accounting years[23]. - The company has established strict confidentiality measures to protect core technologies and is committed to managing the entire R&D cycle to mitigate risks associated with new product development[134]. - The company has acknowledged investment project risks, conducting thorough market analysis and ensuring project feasibility to enhance the likelihood of successful outcomes[136]. Governance and Shareholder Engagement - The board of directors consists of 7 members, including 3 independent directors, ensuring effective governance and decision-making[143]. - The company held multiple shareholder meetings with participation rates of 32.29%, 31.15%, 56.10%, and 51.18% respectively, ensuring shareholder engagement[150]. - The company has established a robust investor relations management system, enhancing transparency and communication with stakeholders[146]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 4.682 million[165]. Environmental Compliance - The company has maintained compliance with multiple environmental laws and regulations, including the Environmental Protection Law and the Water Pollution Prevention Law[196]. - The company has established a wastewater treatment service agreement with a local firm to ensure compliance with discharge standards[197]. - The wastewater treatment system has been upgraded with advanced processes including multi-effect evaporation and Fenton oxidation, enhancing treatment capacity[200]. - The company has committed to ongoing environmental assessments and compliance checks for all new projects[196].

Revenue and Profit - The company's revenue for Q1 2024 was ¥244,395,524.04, a decrease of 27.00% compared to ¥334,785,915.82 in the same period last year[4] - Net profit attributable to shareholders was ¥3,070,728.65, down 80.00% from ¥15,355,110.28 year-on-year[4] - The company reported a basic earnings per share of ¥0.02, down 77.78% from ¥0.09 in the same quarter last year[4] - Net profit for Q1 2024 was ¥3,711,472.71, a decline of 79% from ¥17,525,308.93 in Q1 2023[20] Cash Flow - The net cash flow from operating activities increased by 98.51% to ¥21,248,864.71, compared to ¥10,704,060.35 in Q1 2023[11] - The net cash flow from financing activities surged by 1,424.34% to ¥101,263,266.17, compared to ¥6,643,103.13 in Q1 2023[11] - The company received cash related to operating activities totaling ¥202,674,544.42, a decrease from ¥248,042,987.04 in the previous year[22] - In Q1 2024, the net cash flow from investing activities was -12,909,484.64, compared to -27,232,006.03 in Q1 2023, indicating an improvement[23] - The total cash inflow from financing activities was 536,827,460.79, up from 381,974,721.80 in the same quarter last year, reflecting a 40.6% increase[23] - The company experienced a net increase in cash and cash equivalents of 109,895,640.36 in Q1 2024, contrasting with a decrease of -11,191,652.48 in Q1 2023[23] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,370,087,418.79, reflecting a 4.01% increase from ¥3,240,242,403.84 at the end of the previous year[4] - Total liabilities amounted to ¥1,299,942,942.85, compared to ¥1,174,795,832.63 previously[17] - The company reported cash and cash equivalents of ¥351,284,155.10 at the end of Q1 2024, an increase from ¥238,490,756.82 at the beginning of the period[16] - Accounts receivable stood at ¥271,654,095.00, slightly down from ¥272,117,151.74[16] - Inventory increased to ¥730,067,778.48 from ¥722,624,129.92, indicating a growth in stock levels[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,521[13] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, totaling 43,297,382 shares, with 15,280,000 shares pledged[13] Operating Costs and Expenses - The company’s operating costs decreased by 28.88% to ¥174,821,291.66, down from ¥245,803,460.08 in the previous year[9] - Total operating costs for Q1 2024 were ¥238,473,780.69, down 24% from ¥313,685,870.45 year-over-year[19] - Research and development expenses for Q1 2024 were ¥14,321,901.84, slightly up from ¥13,999,442.81 in Q1 2023[19] Equity and Investments - The company reported a total equity attributable to shareholders of the parent company of ¥2,016,119,568.37, up from ¥2,012,156,809.24 year-over-year[20] - Long-term investments increased to ¥67,022,673.30 from ¥65,119,540.60[16] - The company's equity remains stable with a share capital of ¥189,702,126.00[17] Other Financial Metrics - The weighted average return on equity decreased to 0.15% from 0.89% year-on-year, a decline of 0.74%[4] - Other comprehensive income after tax for Q1 2024 was ¥986,432.02, compared to a loss of ¥1,525,944.83 in Q1 2023[20] - The company has not reported any changes in the status of preferred shareholders or significant changes in shareholding structure[15] Audit Status - The first quarter report for 2024 was not audited, which may affect the reliability of the financial data presented[24]

山东赛托生物科技股份有限公司 一、独立董事的基本情况 本人卿北军，1981年出生，中国国籍，本科学历，会计学专业，中国注册会 计师（非执业会员）。曾任职于深圳南方民和会计师事务所有限责任公司、方大 集团股份有限公司，曾任深圳万润科技股份有限公司董事、财务总监、副总裁。 现任深圳市大洋物流股份有限公司董事会秘书兼财务总监。在2020年11月16日- 2023年12月8日担任公司独立董事。因任期届满离任，本人已不再担任公司任何 职务。 独立董事 2023 年度述职报告 本人作为山东赛托生物科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 《公司章程》等相关法律法规的规定和要求履行独立董事的职务。现将本人2023 年度履行独立董事职责的情况汇报如下： 2023年任职期间，本人任职符合法律法规和规范性文件等规定的独立性要求， 不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会、股东大会情况 2023年度，本人任职期间公司共召开了6次董事会、4次股东大会。本 ...